The Investigational New Drug CDMO Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product (Small Molecule, Large Molecule), By Service (By Small MoleculeContract Development (Bioanalysis and DMPK studies, Toxicology Testing, Pathology and safety pharmacology studies, Drug substance synthetic route development, Drug substance process development, Form selection crystallization process development, Scale-up of drug substance, Preformulation, Preclinical formulation selection, First in Man Formulation/Process Development, Analytical method development/validation, Release testing of drug substance and drug product, Work up Purification Steps, Telescoping & Process Refining, Initial Optimization, Formal stability of drug substance and drug product), By Large Molecule Contract Development (Cell Line development, Process Development), By Small Molecule Contract Manufacturing (Oral Solids, Liquid and Semi-solids, Injectables, Others), By Large Molecule Contract Manufacturing (MABs, Recombinant proteins, Others), By End-User (Pharmaceutical Companies, Biotech Companies, Others).
The Investigational New Drug (IND) Contract Development and Manufacturing Organization (CDMO) market is a vital component of the pharmaceutical industry, catering to the increasing demand for outsourced drug development and manufacturing services. In 2024, the market is experiencing rapid expansion driven by the growing complexity of drug molecules, stringent regulatory requirements, and the need for accelerated development timelines. IND CDMOs offer expertise in formulation development, process optimization, analytical testing, and regulatory compliance, enabling pharmaceutical companies to streamline their drug development pipelines and navigate the challenges of bringing novel therapeutics to market efficiently.
A prominent trend in the Investigational New Drug (IND) Contract Development and Manufacturing Organization (CDMO) market is the escalating outsourcing of drug development activities by pharmaceutical and biotechnology companies. As the pharmaceutical industry continues to face challenges such as rising R&D costs, patent expirations, and the need for innovative therapies, companies are increasingly turning to CDMOs to streamline drug development processes and accelerate time-to-market for investigational new drugs. Outsourcing to CDMOs offers several benefits, including access to specialized expertise, state-of-the-art facilities, and flexible manufacturing capacities, enabling pharmaceutical companies to optimize resource allocation, mitigate risks, and focus on core competencies. This trend reflects the growing reliance on external partners for efficient and cost-effective drug development solutions.
A key driver in the Investigational New Drug CDMO market is the growing demand for specialized expertise and infrastructure to support the development and manufacturing of investigational new drugs. The complexity of modern drug candidates, including biologics, cell and gene therapies, and personalized medicines, necessitates advanced technologies, specialized capabilities, and regulatory compliance throughout the drug development lifecycle. Pharmaceutical companies seek CDMO partners with a track record of success in navigating regulatory requirements, implementing quality systems, and delivering innovative solutions tailored to the unique characteristics of investigational new drugs. CDMOs with expertise in areas such as formulation development, analytical testing, process optimization, and cGMP manufacturing are increasingly sought after to support diverse drug development programs and accelerate therapeutic innovation.
An opportunity for market expansion in the Investigational New Drug CDMO market lies in expanding operations into emerging markets and therapeutic areas with high growth potential. Emerging markets, particularly in Asia-Pacific and Latin America, offer attractive opportunities for CDMOs due to factors such as a growing pharmaceutical industry, favorable regulatory environments, and lower manufacturing costs. By establishing strategic partnerships or setting up local manufacturing facilities in these regions, CDMOs can enhance their global footprint, access new customer segments, and capitalize on the increasing demand for outsourced drug development services. Additionally, focusing on specialized therapeutic areas such as oncology, rare diseases, and orphan drugs presents opportunities to differentiate services, address unmet medical needs, and establish long-term partnerships with pharmaceutical innovators seeking expertise in niche markets.
By Product
Small Molecule
Large Molecule
By Service
By Contract Development (Small Molecule)
Bioanalysis and DMPK studies
Toxicology Testing
Pathology and safety pharmacology studies
Drug substance synthetic route development
Drug substance process development
Form selection crystallization process development
Scale-up of drug substance
Preformulation
Preclinical formulation selection
First in Man Formulation/Process Development
Analytical method development/validation
Release testing of drug substance and drug product
Work up Purification Steps
Telescoping & Process Refining
Initial Optimization
Formal stability of drug substance and drug product
By Contract Development (Large Molecule)
Cell Line development
Process Development
-Upstream
-Downstream
By Contract Manufacturing (Small Molecule)
Oral Solids
Liquid and Semi-solids
Injectables
Others
By Contract Manufacturing (Large Molecule)
MABs
Recombinant proteins
Others
By End-User
Pharmaceutical Companies
Biotech Companies
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Cambrex Corp
Catalent
Charles River Laboratories Inc
Covance Inc
IQVIA Holdings Inc
Lonza
Recipharm AB
Siegfried Holding AG
Syneos Health
Thermo Fisher Scientific Inc
*- List Not Exhaustive
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Investigational New Drug CDMO Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Investigational New Drug CDMO Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Investigational New Drug CDMO Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Investigational New Drug CDMO Market Size Outlook, $ Million, 2021 to 2030
3.2 Investigational New Drug CDMO Market Outlook by Type, $ Million, 2021 to 2030
3.3 Investigational New Drug CDMO Market Outlook by Product, $ Million, 2021 to 2030
3.4 Investigational New Drug CDMO Market Outlook by Application, $ Million, 2021 to 2030
3.5 Investigational New Drug CDMO Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Investigational New Drug CDMO Market Industry
4.2 Key Market Trends in Investigational New Drug CDMO Market Industry
4.3 Potential Opportunities in Investigational New Drug CDMO Market Industry
4.4 Key Challenges in Investigational New Drug CDMO Market Industry
5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Investigational New Drug CDMO Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Investigational New Drug CDMO Market Outlook By Segments
7.1 Investigational New Drug CDMO Market Outlook by Segments
By Product
Small Molecule
Large Molecule
By Service
By Contract Development (Small Molecule)
Bioanalysis and DMPK studies
Toxicology Testing
Pathology and safety pharmacology studies
Drug substance synthetic route development
Drug substance process development
Form selection crystallization process development
Scale-up of drug substance
Preformulation
Preclinical formulation selection
First in Man Formulation/Process Development
Analytical method development/validation
Release testing of drug substance and drug product
Work up Purification Steps
Telescoping & Process Refining
Initial Optimization
Formal stability of drug substance and drug product
By Contract Development (Large Molecule)
Cell Line development
Process Development
-Upstream
-Downstream
By Contract Manufacturing (Small Molecule)
Oral Solids
Liquid and Semi-solids
Injectables
Others
By Contract Manufacturing (Large Molecule)
MABs
Recombinant proteins
Others
By End-User
Pharmaceutical Companies
Biotech Companies
Others
8 North America Investigational New Drug CDMO Market Analysis And Outlook To 2030
8.1 Introduction to North America Investigational New Drug CDMO Markets in 2024
8.2 North America Investigational New Drug CDMO Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Investigational New Drug CDMO Market size Outlook by Segments, 2021-2030
By Product
Small Molecule
Large Molecule
By Service
By Contract Development (Small Molecule)
Bioanalysis and DMPK studies
Toxicology Testing
Pathology and safety pharmacology studies
Drug substance synthetic route development
Drug substance process development
Form selection crystallization process development
Scale-up of drug substance
Preformulation
Preclinical formulation selection
First in Man Formulation/Process Development
Analytical method development/validation
Release testing of drug substance and drug product
Work up Purification Steps
Telescoping & Process Refining
Initial Optimization
Formal stability of drug substance and drug product
By Contract Development (Large Molecule)
Cell Line development
Process Development
-Upstream
-Downstream
By Contract Manufacturing (Small Molecule)
Oral Solids
Liquid and Semi-solids
Injectables
Others
By Contract Manufacturing (Large Molecule)
MABs
Recombinant proteins
Others
By End-User
Pharmaceutical Companies
Biotech Companies
Others
9 Europe Investigational New Drug CDMO Market Analysis And Outlook To 2030
9.1 Introduction to Europe Investigational New Drug CDMO Markets in 2024
9.2 Europe Investigational New Drug CDMO Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Investigational New Drug CDMO Market Size Outlook By Segments, 2021-2030
By Product
Small Molecule
Large Molecule
By Service
By Contract Development (Small Molecule)
Bioanalysis and DMPK studies
Toxicology Testing
Pathology and safety pharmacology studies
Drug substance synthetic route development
Drug substance process development
Form selection crystallization process development
Scale-up of drug substance
Preformulation
Preclinical formulation selection
First in Man Formulation/Process Development
Analytical method development/validation
Release testing of drug substance and drug product
Work up Purification Steps
Telescoping & Process Refining
Initial Optimization
Formal stability of drug substance and drug product
By Contract Development (Large Molecule)
Cell Line development
Process Development
-Upstream
-Downstream
By Contract Manufacturing (Small Molecule)
Oral Solids
Liquid and Semi-solids
Injectables
Others
By Contract Manufacturing (Large Molecule)
MABs
Recombinant proteins
Others
By End-User
Pharmaceutical Companies
Biotech Companies
Others
10 Asia Pacific Investigational New Drug CDMO Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Investigational New Drug CDMO Markets in 2024
10.2 Asia Pacific Investigational New Drug CDMO Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Investigational New Drug CDMO Market size Outlook by Segments, 2021-2030
By Product
Small Molecule
Large Molecule
By Service
By Contract Development (Small Molecule)
Bioanalysis and DMPK studies
Toxicology Testing
Pathology and safety pharmacology studies
Drug substance synthetic route development
Drug substance process development
Form selection crystallization process development
Scale-up of drug substance
Preformulation
Preclinical formulation selection
First in Man Formulation/Process Development
Analytical method development/validation
Release testing of drug substance and drug product
Work up Purification Steps
Telescoping & Process Refining
Initial Optimization
Formal stability of drug substance and drug product
By Contract Development (Large Molecule)
Cell Line development
Process Development
-Upstream
-Downstream
By Contract Manufacturing (Small Molecule)
Oral Solids
Liquid and Semi-solids
Injectables
Others
By Contract Manufacturing (Large Molecule)
MABs
Recombinant proteins
Others
By End-User
Pharmaceutical Companies
Biotech Companies
Others
11 South America Investigational New Drug CDMO Market Analysis And Outlook To 2030
11.1 Introduction to South America Investigational New Drug CDMO Markets in 2024
11.2 South America Investigational New Drug CDMO Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Investigational New Drug CDMO Market size Outlook by Segments, 2021-2030
By Product
Small Molecule
Large Molecule
By Service
By Contract Development (Small Molecule)
Bioanalysis and DMPK studies
Toxicology Testing
Pathology and safety pharmacology studies
Drug substance synthetic route development
Drug substance process development
Form selection crystallization process development
Scale-up of drug substance
Preformulation
Preclinical formulation selection
First in Man Formulation/Process Development
Analytical method development/validation
Release testing of drug substance and drug product
Work up Purification Steps
Telescoping & Process Refining
Initial Optimization
Formal stability of drug substance and drug product
By Contract Development (Large Molecule)
Cell Line development
Process Development
-Upstream
-Downstream
By Contract Manufacturing (Small Molecule)
Oral Solids
Liquid and Semi-solids
Injectables
Others
By Contract Manufacturing (Large Molecule)
MABs
Recombinant proteins
Others
By End-User
Pharmaceutical Companies
Biotech Companies
Others
12 Middle East And Africa Investigational New Drug CDMO Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Investigational New Drug CDMO Markets in 2024
12.2 Middle East and Africa Investigational New Drug CDMO Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Investigational New Drug CDMO Market size Outlook by Segments, 2021-2030
By Product
Small Molecule
Large Molecule
By Service
By Contract Development (Small Molecule)
Bioanalysis and DMPK studies
Toxicology Testing
Pathology and safety pharmacology studies
Drug substance synthetic route development
Drug substance process development
Form selection crystallization process development
Scale-up of drug substance
Preformulation
Preclinical formulation selection
First in Man Formulation/Process Development
Analytical method development/validation
Release testing of drug substance and drug product
Work up Purification Steps
Telescoping & Process Refining
Initial Optimization
Formal stability of drug substance and drug product
By Contract Development (Large Molecule)
Cell Line development
Process Development
-Upstream
-Downstream
By Contract Manufacturing (Small Molecule)
Oral Solids
Liquid and Semi-solids
Injectables
Others
By Contract Manufacturing (Large Molecule)
MABs
Recombinant proteins
Others
By End-User
Pharmaceutical Companies
Biotech Companies
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Cambrex Corp
Catalent
Charles River Laboratories Inc
Covance Inc
IQVIA Holdings Inc
Lonza
Recipharm AB
Siegfried Holding AG
Syneos Health
Thermo Fisher Scientific Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Product
Small Molecule
Large Molecule
By Service
By Contract Development (Small Molecule)
Bioanalysis and DMPK studies
Toxicology Testing
Pathology and safety pharmacology studies
Drug substance synthetic route development
Drug substance process development
Form selection crystallization process development
Scale-up of drug substance
Preformulation
Preclinical formulation selection
First in Man Formulation/Process Development
Analytical method development/validation
Release testing of drug substance and drug product
Work up Purification Steps
Telescoping & Process Refining
Initial Optimization
Formal stability of drug substance and drug product
By Contract Development (Large Molecule)
Cell Line development
Process Development
-Upstream
-Downstream
By Contract Manufacturing (Small Molecule)
Oral Solids
Liquid and Semi-solids
Injectables
Others
By Contract Manufacturing (Large Molecule)
MABs
Recombinant proteins
Others
By End-User
Pharmaceutical Companies
Biotech Companies
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
The global Investigational New Drug CDMO Market is one of the lucrative growth markets, poised to register a 7.5% growth (CAGR) between 2024 and 2032.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Cambrex Corp, Catalent, Charles River Laboratories Inc, Covance Inc, IQVIA Holdings Inc, Lonza, Recipharm AB, Siegfried Holding AG, Syneos Health, Thermo Fisher Scientific Inc
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume